JP2016504400A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504400A5
JP2016504400A5 JP2015552060A JP2015552060A JP2016504400A5 JP 2016504400 A5 JP2016504400 A5 JP 2016504400A5 JP 2015552060 A JP2015552060 A JP 2015552060A JP 2015552060 A JP2015552060 A JP 2015552060A JP 2016504400 A5 JP2016504400 A5 JP 2016504400A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
aryl
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015552060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504400A (ja
JP6276289B2 (ja
Filing date
Publication date
Priority claimed from GBGB1300435.3A external-priority patent/GB201300435D0/en
Application filed filed Critical
Publication of JP2016504400A publication Critical patent/JP2016504400A/ja
Publication of JP2016504400A5 publication Critical patent/JP2016504400A5/ja
Application granted granted Critical
Publication of JP6276289B2 publication Critical patent/JP6276289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015552060A 2013-01-10 2014-01-10 ベンジリデングアニジン誘導体、及びタンパク質ミスフォールディング疾患を治療するための治療的使用 Active JP6276289B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1300435.3 2013-01-10
GBGB1300435.3A GB201300435D0 (en) 2013-01-10 2013-01-10 Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
PCT/EP2014/050422 WO2014108520A1 (en) 2013-01-10 2014-01-10 Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases

Publications (3)

Publication Number Publication Date
JP2016504400A JP2016504400A (ja) 2016-02-12
JP2016504400A5 true JP2016504400A5 (cg-RX-API-DMAC10.html) 2017-01-05
JP6276289B2 JP6276289B2 (ja) 2018-02-07

Family

ID=47757796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552060A Active JP6276289B2 (ja) 2013-01-10 2014-01-10 ベンジリデングアニジン誘導体、及びタンパク質ミスフォールディング疾患を治療するための治療的使用

Country Status (21)

Country Link
US (4) US9682943B2 (cg-RX-API-DMAC10.html)
EP (2) EP3115357B1 (cg-RX-API-DMAC10.html)
JP (1) JP6276289B2 (cg-RX-API-DMAC10.html)
KR (1) KR102166665B1 (cg-RX-API-DMAC10.html)
CN (1) CN105189452B (cg-RX-API-DMAC10.html)
AU (2) AU2014204831C1 (cg-RX-API-DMAC10.html)
CA (1) CA2896976C (cg-RX-API-DMAC10.html)
DK (1) DK2943467T3 (cg-RX-API-DMAC10.html)
ES (2) ES2594378T3 (cg-RX-API-DMAC10.html)
GB (1) GB201300435D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20161208T1 (cg-RX-API-DMAC10.html)
HU (1) HUE030848T2 (cg-RX-API-DMAC10.html)
IL (1) IL239629B (cg-RX-API-DMAC10.html)
LT (1) LT2943467T (cg-RX-API-DMAC10.html)
MX (1) MX370491B (cg-RX-API-DMAC10.html)
PL (1) PL2943467T3 (cg-RX-API-DMAC10.html)
PT (1) PT2943467T (cg-RX-API-DMAC10.html)
RS (1) RS55185B1 (cg-RX-API-DMAC10.html)
RU (1) RU2654910C2 (cg-RX-API-DMAC10.html)
SI (1) SI2943467T1 (cg-RX-API-DMAC10.html)
WO (1) WO2014108520A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300435D0 (en) 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
WO2014138298A1 (en) 2013-03-05 2014-09-12 University Of Chicago Treatment of demyelinating disorders
KR102387615B1 (ko) * 2014-07-02 2022-04-18 인플렉티스 바이오사이언스 단백질질환의 치료를 위한 벤질리덴구아니딘 유도체들의 신규한 치료적 용도
KR102572217B1 (ko) * 2015-04-08 2023-08-28 유나이티드 킹덤 리서치 앤드 이노베이션 포스파타제 선택적 및 비 선택적 포스파타제 억제제의 선별 방법
US9501793B1 (en) * 2015-06-04 2016-11-22 Herofi, Inc. Archetecture and associated methodology for data standardization and utilization in retail industry applications
AU2016304331B2 (en) * 2015-07-31 2021-08-05 Inflectis Bioscience Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent.
US20180230105A1 (en) 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
US11166464B2 (en) * 2017-03-06 2021-11-09 The United States Of America, As Represented By The Secretary Of Agriculture Self-assembled active agents
US20210177814A1 (en) 2018-05-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies
CN113072467B (zh) * 2021-03-24 2022-04-12 南方医科大学 含取代胍基衍生物及其在制备破骨细胞分化抑制剂上的应用
WO2024105168A1 (en) 2022-11-18 2024-05-23 Inflectis Bioscience Novel combinations useful for the treatments of als
US20240293343A1 (en) 2023-02-13 2024-09-05 Inflectis Bioscience Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications
EP4680216A1 (en) * 2023-03-16 2026-01-21 Kyoto Prefectural Public University Corporation Sephin1 and related compounds for the treatment of diseases and disorders amenable to treatment by ampk activation and/or chop inhibition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1223492A (en) 1967-10-13 1971-02-24 American Home Prod Guanidines
US3541218A (en) * 1969-06-18 1970-11-17 Lilly Co Eli Omicron-fluorobenzylaminoguanidine for diabetes
SE7607653L (sv) 1976-07-05 1978-01-06 Haessle Ab Substituerade triazoler
JPH06510760A (ja) * 1991-08-27 1994-12-01 ジ・アップジョン・カンパニー 代謝障害および代謝の治療法
DE793646T1 (de) * 1994-11-23 1999-12-30 Pharmacia & Upjohn Co., Kalamazoo Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus
US6335339B1 (en) 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
AU7802700A (en) 1999-10-06 2001-05-10 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US6518269B1 (en) 2000-07-28 2003-02-11 University Of Arizona Foundation Cancer treatment
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
FR2812812B1 (fr) 2000-08-08 2002-10-11 Philippe Gorny Medicament destine notamment a combattre les dysfonctions sexuelles
BRPI0414622A (pt) * 2003-09-25 2006-11-07 Acadia Pharm Inc métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias
CN1875271A (zh) * 2003-09-25 2006-12-06 阿卡蒂亚药品公司 用神经肽ff受体2激动剂治疗神经痛
ATE429910T1 (de) * 2006-10-04 2009-05-15 Centre Nat Rech Scient Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen
EP1908464A1 (en) * 2006-10-04 2008-04-09 Centre National De La Recherche Scientifique (Cnrs) Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases
WO2008091681A2 (en) 2007-01-23 2008-07-31 Housey Gerard M Theramutein modulators
US20120202814A1 (en) 2009-10-02 2012-08-09 Università Degli Studi Di Siena Compounds with ddx3 inhibitory activity and uses thereof
WO2011097607A1 (en) 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
EP2595965B1 (en) 2010-07-20 2016-06-22 Vestaron Corporation Insecticidal triazines and pyrimidines
US20130274235A1 (en) * 2010-10-08 2013-10-17 The General Hospital Corporation Treatment of motor neuron disease
GB201300435D0 (en) * 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases

Similar Documents

Publication Publication Date Title
JP2016504400A5 (cg-RX-API-DMAC10.html)
RU2015127827A (ru) Производные бензилиденгуанидина и их терапевтическое применение для лечения заболеваний, связанных с неправильным сворачиванием белков
JP2017509586A5 (cg-RX-API-DMAC10.html)
AR122902A2 (es) Compuestos terapéuticamente activos y sus métodos de preparación
JP2017071634A5 (cg-RX-API-DMAC10.html)
JP2015520769A5 (cg-RX-API-DMAC10.html)
JP2016505637A5 (cg-RX-API-DMAC10.html)
JP2014521688A5 (cg-RX-API-DMAC10.html)
JP2013537203A5 (cg-RX-API-DMAC10.html)
JP2016503797A5 (cg-RX-API-DMAC10.html)
JP2016506961A5 (cg-RX-API-DMAC10.html)
PE20141282A1 (es) Derivados de 8-carbamoil-2-(2,3-pirid-6-ilo di sustituido)-1,2,3,4-tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
JP2017533968A5 (cg-RX-API-DMAC10.html)
JP2013533879A5 (cg-RX-API-DMAC10.html)
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
JP2014511891A5 (cg-RX-API-DMAC10.html)
JP2014511892A5 (cg-RX-API-DMAC10.html)
JP2016506962A5 (cg-RX-API-DMAC10.html)
JP2016513130A5 (cg-RX-API-DMAC10.html)
JP2017504635A5 (cg-RX-API-DMAC10.html)
JP2016507575A5 (cg-RX-API-DMAC10.html)
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
JP2015500842A5 (cg-RX-API-DMAC10.html)
JP2016513696A5 (cg-RX-API-DMAC10.html)
JP2014510147A5 (cg-RX-API-DMAC10.html)